Gruenenthal Gmbh

Volcano Corporation

Astellas Pharma Gmbh

Abbott Laboratories Vascular Enterprises Limited

Viacord LLC

Mlm Medical Labs Gmbh

Viacell, Inc.

Stephan Wnendt

Johannes Schneider

Oswald K Zimmer

Gerd J Steffens

Regina Heinzel-Wieland

Kai Zwingenberger

Bernd Sundermann

Robert Julian Dickinson

William Howes

Elvin Nix

Werner Guenter Englberger

Hagen-Heinrich Hennies

Derek John Saunders

Wolfgang Werner Strassburger

Werner Winter

Randolf Von Oepen

Helmut Heinrich Buschmann

Babette-Yvonne Koegel

Andreas Muhs

Axel Grandt

Michael Finkam

Ulrich G Seipp

Guenter Lorenz

Horst R Boehlke

Cornelia Geist

Elke Janocha

Elke Reiss-Mueller

Hoerst Boehlke

Bernd Kuttler

Gerhard Lang

Uwe Teubert

Bernd Zimmermann

Heide Hecker-Kia

Norbert Ulbrich

Michaela Akermann

Thomas Krueger

The invention relates to a container system for transport of biological material comprising a container casing and an insulating device, wherein the container casing defines a container interior space for accommodation of the insulating device and for accommodation of biological material to be transported, and wherein the insulating device is constituted of at least two insulating portions, which are formed so as to surround the biological material inside the container interior space. The invention further relates to uses of such a container system for packaging and transport of biological material, as well as methods of packaging biological material for transport.

Container system for transport of biological material, uses thereof and methods of packaging

An intravascular ultrasonic imaging catheter is provided with a flexible circuit electrically coupled to a transducer array mounted on the distal end of the catheter, a portion of the flexible circuit being helically wound about the catheter in order to enhance the flexibility of the circuit. The catheter may be a balloon catheter which is also provided with a stent mounted on the balloon, the stent carrying one or more drugs designed to be eluted or washed into a patient's blood stream after the stent has been delivered, by a the balloon catheter, into a target area within the patient's vascular system.

Ultrasonic imaging catheters

The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal.

Treatment of ischemia using stem cells

Implants and methods of making same are provided for treatment or prophylaxis of coronary or peripheral vascular constrictions or vascular occlusions, and particularly, stenoses or restenoses, that comprise FK506 in chemically covalently bound, non-covalently bound or physically immobilized form.

Medical implants containing FK506 (tacrolimus)

4-aminocyclohexanol compounds, processes for their preparation, pharmaceutical formulations comprising these compounds and the use of substituted 4-aminocyclohexanol compounds for the preparation of pharmaceutical formulations and for the treatment of diverse indications, including, without limitation, pain.

Substituted 4-aminocyclohexanol compounds

Substituted 4-aminocyclohexanols, methods of producing the same, pharmaceuticals containing these compounds, the use of substituted 4-aminocyclohexanols for producing pharmaceutical compositions for the treatment of various indications, in particular pain, and for related treatment methods.

Substituted 4-aminocyclohexanols

An intravascular ultrasonic imaging catheter is provided with a flexible circuit electrically coupled to a transducer array mounted on the distal end of the catheter, a portion of the flexible circuit being helically wound about the catheter in order to enhance the flexibility of the circuit. The catheter may be a balloon catheter which is also provided with a stent mounted on the balloon, the stent carrying one or more drugs designed to be eluted or washed into a patient's blood stream after the stent has been delivered, by the balloon catheter, into a target area within the patient's vascular system.

Ultrasonic imagining catheters

The invention relates to the use of substituted 4-amino-1-phenylbutan-2-ol compounds in the form of their racemates, enantiomers, diastereomers or corresponding bases or corresponding salts of physiologically acceptable acids as regulators for the nociceptin/orphanin-FQ ligand ORL1 receptor system and for the production of medicaments.

Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments

Use of catechol derivatives as proteinase inhibitors

Lactam derivatives as immunomodulating agents

A method for agonizing or antagonizing the ORL1 (opioid receptor-like) receptor of the nociceptin/orphanin FQ ligand ORL1 receptor system using a morphinan compound of the general formula I or derivatives thereof. Also disclosed are methods for treating neuropathic pain and/or anxiolysis and/or depression and/or diuresis and/or urinary incontinence and/or hypotension and or hypertension and/or senile dementia and/or Alzheimer's disease and/or general cognitive disfunctions an/or tinnitus and/or impaired hearing and/or epilepsy and/or obesity and/or cachexia.

Use of morphine derivatives as medicaments for the treatment of neuropathic problems

Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action

Chimeric proteins with fibrinolytic and thrombin-inhibiting properties having a plasminogen-activating amino acid sequence which is linked at its C-terminal end to a thrombin-inhibiting amino acid sequence.

Chimeric proteins having fibrinolytic and thrombin-inhibiting properties

Compounds analogous to thalidomide from the class comprising piperidine-2,6-diones are described, as are a method of preparing them and their use in drugs.

Compounds analogous to thalidomide from the class comprising

Growing community of inventors

Aachen, Germany

Stephan Wnendt